View Author
dai: 298691442

Bie, M. de

(Maaike de Bie)


cmc -544 rearrangement -544 leukemia cd 22 expression ef ficacy calicheamicin expression ficacy precursor-ball patient lymphoblastic leukemia van dongen jjm bcp-all figure internalization analysis segment lymphoblastic level sensitivity receptor bcp-all cells blood ic 50 values target 37 1 c clonal cmc -544. childhood concentration death t-cell b-cell disease study cell lines dongen germline saturation relapse sample cd 22 ags intracellular detection value antibody j segments aml cells ozogamicin -544. bcp-all jf binding cd 22 van wering sequence gemtuzumab ozogamicin joining diagnosis incubation region szczepanski wolvers-tettero ilm treatment junctional cell survival intracellular accumulation target cells recombination primers rq-pcr cd 33 ags cd 22 ratio -544-induced survival primer gemtuzumab myeloid leukemia cell surface calicheamicin sensitivity




2 Most Recent Publications

The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells (Article)
Vries, J.F. de Zwaan, C.M. Bie, M. de Voerman, J.S. Boer, M.L. den Dongen, J.J.M. van Velden, V.H.J. van der
2012-02-01
Vdelta2-Jalpha rearrangements are frequent in precursor-B-acute lymphoblastic leukemia but rare in normal lymphoid cells (Article)
Szczepański, T. Velden, V.H.J. van der Hoogeveen, P.G. Bie, M. de Jacobs, D.C. Wering, E.R. van Dongen, J.J.M. van
2004-01-01